PTC Therapeutics, Inc. has selected a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation, triggering a $10 million payment to PTC from Roche. The SMA program, initially developed by PTC Therapeutics and the SMA Foundation, was licensed to Roche in November 2011. PTC received $30 million upfront, is entitled to $10 million for the selection of a development candidate, and may receive as much as an additional $450 million upon successful deve...